Rationale for combined therapies in severe-to-critical COVID-19 patients

Frontiers in Immunology

Immunology

Luis M. Hernández-Blasco¹  Jose Carlos Sanjuan-Gimenez¹  Francisco Jaime¹  Fabian Tarín¹  Cristina Alenda¹  Etelvina Andreu²  Jose M. Sempere-Ortells³  Rut Meseguer⁴  Esperanza Merino⁵  Karima Al-Akioui-Sanz⁶  Francisco M. Marco⁷  Aitor Gonzaga⁸  Bernat Soria⁹  Sergio Querol^1,10  Rosa Goterris^1,11  Alberto Borobia^1,12  Manuel Guerreiro^1,13  Juan R. Tejedo^1,14  Abdelkrim Hmadcha^1,15  Alejandro Martín-Quirós^1,16  Carlos Cañada-Illana^1,16  Cristobal Aguilar-Gallardo^1,17  Ana Bonora^1,17  Jose L. Poveda^1,17  Carlos Solano^1,18  Cristina Ferreras^1,19  Antonio Pérez-Martínez^2,20  José Ferreres^2,21  Juan Carlos Figueira^2,22  Ángel Robles-Marhuenda^2,23  Loreto Maciá^2,24  Cristina Eguizabal^2,25  Bárbara Soria-Juan^2,26  Jose L. Vicario^2,27  Guillermo Lopez-Lluch^2,28  Cristina Arbona^2,29 

[1] Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain;Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain;Applied Physics Department, Miguel Hernández University, Elche, Spain;Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain;Biotechnology Department, University of Alicante, Alicante, Spain;Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain;Clinic University Hospital, Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA) Health Research Institute, Valencia, Spain;Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain;Department of Clinical Medicine, Miguel Hernández University, Elche, Spain;Infectious Diseases Unit, Dr. Balmis General University Hospital, Alicante, Spain;Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain;Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La Paz, Madrid, Spain;Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain;Immunology Department, Dr. Balmis General University Hospital, Alicante, Spain;Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain;Institute of Bioengineering, Miguel Hernández University, Elche, Spain;Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain;Institute of Bioengineering, Miguel Hernández University, Elche, Spain;Biomedical Research Network for Diabetes and Related Metabolic Diseases-Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) of the Carlos III Health Institute (ISCIII), Madrid, Spain;Banc de Sang I Teixits, Barcelona, Spain;Clinic University Hospital, Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA) Health Research Institute, Valencia, Spain;Clinical Pharmacology Department, La Paz University Hospital, School of Medicine, Universidad Autónoma de Madrid, IdiPAz, Madrid, Spain;Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain;Department of Molecular Biology and Biochemical Engineering, University Pablo de Olavide, Seville, Spain;Biomedical Research Network for Diabetes and Related Metabolic Diseases-Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) of the Carlos III Health Institute (ISCIII), Madrid, Spain;Department of Molecular Biology and Biochemical Engineering, University Pablo de Olavide, Seville, Spain;Biosanitary Research Institute (IIB-VIU), Valencian International University (VIU), Valencia, Spain;Emergency Department, Hospital Universitario La Paz – IdiPAZ, Madrid, Spain;Health Research Institute Hospital La Fe, Valencia, Spain;Hematology Service, Hospital Clínico Universitario, Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA), Valencia, Spain;Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La Paz, Madrid, Spain;Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La Paz, Madrid, Spain;Department of Pediatrics, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain;Intensive Care Service, Hospital Clinico Universitario, Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA), Valencia, Spain;Intensive Care Unit, Hospital Universitario La Paz – IdiPAZ, Madrid, Spain;Internal Medicine Department, Hospital Universitario La Paz – IdiPAZ, Madrid, Spain;Nursing Department, University of Alicante, Alicante, Spain;Research Unit, Basque Center for Blood Transfusion and Human Tissues, Galdakao, Spain;Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain;Réseau Hospitalier Neuchâtelois, Hôpital Pourtalès, Neuchâtel, Switzerland;Transfusion Center of the Autonomous Community of Madrid, Madrid, Spain;University Pablo de Olavide, Centro Andaluz de Biología del Desarrollo - Consejo Superior de Investigaciones Científicas (CABD-CSIC), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Sevilla, Spain;Valencian Community Blood Transfusion Center, Valencia, Spain;

关键词: COVID-19;    cytokine storm;    immunomodulation;    mesenchymal stromal cells;    SARS-CoV-2;    advanced therapies;   

DOI  :  10.3389/fimmu.2023.1232472

 received in 2023-05-31, accepted in 2023-08-22,  发布年份 2023

来源: Frontiers

【 摘 要 】

An unprecedented global social and economic impact as well as a significant number of fatalities have been brought on by the coronavirus disease 2019 (COVID-19), produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute SARS-CoV-2 infection can, in certain situations, cause immunological abnormalities, leading to an anomalous innate and adaptive immune response. While most patients only experience mild symptoms and recover without the need for mechanical ventilation, a substantial percentage of those who are affected develop severe respiratory illness, which can be fatal. The absence of effective therapies when disease progresses to a very severe condition coupled with the incomplete understanding of COVID-19’s pathogenesis triggers the need to develop innovative therapeutic approaches for patients at high risk of mortality. As a result, we investigate the potential contribution of promising combinatorial cell therapy to prevent death in critical patients.

【 授权许可】

Unknown   
Copyright © 2023 Gonzaga, Andreu, Hernández-Blasco, Meseguer, Al-Akioui-Sanz, Soria-Juan, Sanjuan-Gimenez, Ferreras, Tejedo, Lopez-Lluch, Goterris, Maciá, Sempere-Ortells, Hmadcha, Borobia, Vicario, Bonora, Aguilar-Gallardo, Poveda, Arbona, Alenda, Tarín, Marco, Merino, Jaime, Ferreres, Figueira, Cañada-Illana, Querol, Guerreiro, Eguizabal, Martín-Quirós, Robles-Marhuenda, Pérez-Martínez, Solano and Soria